Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors

Retrovirology

Volumn 6, Issue , 2009, Pages

  Falkensammer, Barbara ^a   Rubner, Barbara ^a   Hiltgartner, Alexander ^a   Wilflingseder, Doris ^a   Hennig, Christiane Stahl ^b   Kuate, Seraphin ^c   Überla, Klaus ^c   Norley, Stephen ^d   Strasak, Alexander ^a   Racz, Paul ^e   Stoiber, Heribert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b GERMAN PRIMATE CENTER   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d ROBERT KOCH INSTITUTE   (Germany)

^e BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIGEN; VIRUS RNA; COMPLEMENT; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; INFECTION CONTROL; MALE; MURINE LEUKEMIA VIRUS; NONHUMAN; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS ENVELOPE; VIRUS INFECTION; VIRUS LOAD; VIRUS PARTICLE; VIRUS TITRATION; AEROSOL; ANIMAL; BLOOD; GENE VECTOR; GENETICS; HUMAN ADENOVIRUS; IMMUNOLOGY; MACACA; MONKEY DISEASE; PALATINE TONSIL; SERODIAGNOSIS; VIROLOGY;

ANIMALIA; MACACA; MACACA MULATTA; MURINE LEUKEMIA VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS;

ADENOVIRUSES, HUMAN; AEROSOLS; ANIMALS; ANTIBODIES, VIRAL; COMPLEMENT SYSTEM PROTEINS; GENETIC VECTORS; LEUKEMIA VIRUS, MURINE; MACACA MULATTA; NEUTRALIZATION TESTS; PALATINE TONSIL; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD;

EID: 68049138077     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-6-60     Document Type: Article

References (50)

1. Aasa-Chapman MM Hayman A Newton P Cornforth D Williams I Borrow P Balfe P McKnight A Development of the antibody response in acute HIV-1 infection AIDS 2004, 18:371-81 10.1097/00002030-200402200-00002 15090788
2. Lindbäck S Thorstensson R Karlsson AC von Sydow M Flamholc L Blaxhult A Sönnerborg A Biberfeld G Gaines H Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group AIDS 2000, 14:2333-9 10.1097/ 00002030-200010200-00014 11089621
3. Wei X Decker JM Wang S Hui H Kappes JC Wu X Salazar-Gonzalez JF Salazar MG Kilby JM Saag MS Komarova NL Nowak MA Hahn BH Kwong PD Shaw GM Antibody neutralization and escape by HIV-1 Nature 2003, 422:307-12 10.1038/nature01470 12646921
4. Falkensammer B Freißmuth D Hübner L Speth C Dierich MP Stoiber H Changes in HIV-specific antibody responses and neutralization titers in patients under ART Front Biosci 2007, 12:2148-58 10.2741/2218 17127452
5. Sawyer LA Katzenstein DA Hendry RM Boone EJ Vujcic LK Williams CC Zeger SL Saah AJ Rinaldo CR Phair JP Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection AIDS Res Hum Retroviruses 1990, 6:341-56 10.1089/aid.1990.6.341 1971182
6. Banks ND Kinsey N Clements J Hildreth JE Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS AIDS Res Hum Retroviruses 2002, 18:1197-205 10.1089/08892220260387940 12487826
7. Forthal DN Landucci G Keenan B Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count AIDS Res Hum Retroviruses 2001, 17:553-61 10.1089/08892220151126661 11350669
8. Gómez-Román VR Patterson LJ Venzon D Liewehr D Aldrich K Florese R Robert-Guroff M Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251 J Immunol 2005, 174:2185-9 15699150
9. Alsmadi O Herz R Murphy E Pinter A Tilley SA A novel antibody-dependent cellular cytotoxicity epitope in gp120 is identified by two monoclonal antibodies isolated from a long-term survivor of human immunodeficiency virus type 1 infection J Virol 1997, 71:925-33 191140 8995609
10. Gauduin MC Parren PW Weir R Barbas CF Burton DR Koup RA Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1 Nat Med 1997, 3:1389-93 10.1038/nm1297-1389 9396610
11. Aasa-Chapman MM Holuigue S Aubin K Wong M Jones NA Cornforth D Pellegrino P Newton P Williams I Borrow P McKnight A Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection J Virol 2005, 79:2823-30 548453 15709001 10.1128/ JVI.79.5.2823-2830.2005
12. Huber M Fischer M Misselwitz B Manrique A Kuster H Niederöst B Weber R von Wyl V Günthard HF Trkola A Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection PLoS Med 2006, 3:e441 1637124 17121450 10.1371/ journal.pmed.0030441
13. Trkola A Kuster H Rusert P Joos B Fischer M Leemann C Manrique A Huber M Rehr M Oxenius A Weber R Stiegler G Vcelar B Katinger H Aceto L Günthard HF Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies Nat Med 2005, 11:615-22 10.1038/nm1244 15880120
14. Evans DT Bricker JE Desrosiers RC A novel approach for producing lentiviruses that are limited to a single cycle of infection J Virol 2004, 78:11715-25 523244 15479813 10.1128/JVI.78.21.11715-11725.2004
15. Kuate S Stahl-Hennig C ten Haaf P Heeney J Uberla K Single-cycle immunodeficiency viruses provide strategies for uncoupling in vivo expression levels from viral replicative capacity and for mimicking live-attenuated SIV vaccines Virology 2003, 313:653-62 10.1016/ S0042-6822(03)00388-X 12954231
16. Stahl-Hennig C Steinman RM Ten Haaft P Uberla K Stolte N Saeland S Tenner-Racz K Racz P The simian immunodeficiency virus deltaNef vaccine, after application to the tonsils of Rhesus macaques, replicates primarily within CD4(+) T cells and elicits a local perforin-positive CD8(+) T-cell response J Virol 2002, 76:688-96 136843 11752159 10.1128/ JVI.76.2.688-696.2002
17. Tenner-Racz K Stahl Hennig C Uberla K Stoiber H Ignatius R Heeney J Steinman RM Racz P Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus Proc Natl Acad Sci USA 2004, 101:3017-22 365737 14970317 10.1073/pnas.0308677101
18. Gundlach BR Lewis MG Sopper S Schnell T Sodroski J Stahl-Hennig C Uberla K Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain J Virol 2000, 74:3537-42 111861 10729127 10.1128/JVI.74.8.3537-3542.2000
19. Hofmann-Lehmann R Vlasak J Williams A Chenine A McClure H Anderson D O'Neil S Ruprecht R Live-attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation AIDS 2003, 17:157-166 10.1097/00002030-200301240-00004 12545074
20. Burns JC Friedmann T Driever W Burrascano M Yee JK Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells Proc Natl Acad Sci USA 1993, 90:8033-7 47282 8396259 10.1073/pnas.90.17.8033
21. Stahl-Hennig C Kuate S Franz M Suh YS Stoiber H Sauermann U Tenner-Racz K Norley S Park KS Sung YC Steinman R Racz P Uberla K Atraumatic oral spray immunization with replication-deficient viral vector vaccines J Virol 2007, 81:13180-90 2169087 17898066 10.1128/JVI.01400-07
22. Suh YS Park KS Sauermann U Franz M Norley S Wilfingseder D Stoiber H Fagrouch Z Heeney J Hunsmann G Stahl-Hennig C Sung YC Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model Vaccine 2006, 24:1811-20 16274888
23. Evans DT Bricker JE Sanford HB Lang S Carville A Richardson BA Piatak M Lifson JD Mansfield KG Desrosiers RC Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239 J Virol 2005, 79:7707-20 1143664 15919923 10.1128/ JVI.79.12.7707-7720.2005
24. Lifson JD Nowak MA Goldstein S Rossio JL Kinter A Vasquez G Wiltrout TA Brown C Schneider D Wahl L Lloyd AL Williams J Elkins WR Fauci AS Hirsch VM The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection J Virol 1997, 71:9508-14 230257 9371613
25. Zhang ZQ Schleif WA Casimiro DR Handt L Chen M Davies ME Liang X Fu TM Tang A Wilson KA McElhaugh M Carella A Tan C Connolly B Hill S Klein H Emini EA Shiver JW The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P Virology 2004, 320:75-84 10.1016/j.virol.2003.11.017 15003864
26. Quinnan GV Yu XF Lewis MG Zhang PF Sutter G Silvera P Dong M Choudhary A Sarkis PT Bouma P Zhang Z Montefiori DC Vancott TC Broder CC Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: Correlations with neutralizing antibodies and cytotoxic T cells J Virol 2005, 79:3358-69 1075715 15731230 10.1128/JVI.79.6.3358-3369.2005
27. Trkola A Kuster H Rusert P von Wyl V Leemann C Weber R Stiegler G Katinger H Joos B Günthard HF In vivo efficacy of human immunodeficiency virus neutralizing antibodies: Estimates for protective titers J Virol 2008, 82:1591-9 2224433 18032508 10.1128/JVI.01792-07
28. Huber M Trkola A Humoral immunity to HIV-1: Neutralization and beyond J Intern Med 2007, 262:5-25 10.1111/j.1365-2796.2007.01819.x 17598812
29. Florese RH Van Rompay KK Aldrich K Forthal DN Landucci G Mahalanabis M Haigwood N Venzon D Kalyanaraman VS Marthas ML Robert-Guroff M Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge J Immunol 2006, 177:4028-36 16951366
30. Hessell AJ Hangartner L Hunter M Havenith CE Beurskens FJ Bakker JM Lanigan CM Landucci G Forthal DN Parren PW Marx PA Burton DR Fc receptor but not complement binding is important in antibody protection against HIV Nature 2007, 449:101-4 10.1038/nature06106 17805298
31. Doepper S Stoiber H Kacani L Sprinzl G Steindl F Prodinger WM Dierich MP B cell-mediated infection of stimulated and unstimulated autologous T lymphocytes with HIV-1: Role of complement Immunobiology 2000, 202:293-305 11045664
32. Döpper S Wilflingseder D Prodinger WM Stiegler G Speth C Dierich MP Stoiber H Mechanism(s) promoting HIV-1 infection of primary unstimulated T lymphocytes in autologous B cell/T cell co-cultures Eur J Immunol 2003, 33:2098-107 10.1002/eji.200323932 12884283
33. Pruenster M Wilflingseder D Bánki Z Ammann CG Muellauer B Meyer M Speth C Dierich MP Stoiber H C-type lectin-independent interaction of complement opsonized HIV with monocyte-derived dendritic cells Eur J Immunol 2005, 35:2691-8 10.1002/eji.200425940 16094691
34. Stoiber H Pruenster M Ammann CG Dierich MP Complement-opsonized HIV: The free rider on its way to infection Mol Immunol 2005, 42:153-60 10.1016/ j.molimm.2004.06.024 15488605
35. Sullivan BL Takefman DM Spear GT Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism Virology 1998, 248:173-81 10.1006/ viro.1998.9289 9721226
36. Scherl M Posch U Obermoser G Ammann C Sepp N Ulmer H Dierich MP Stoiber H Falkensammer B Targeting human immunodeficiency virus type 1 with antibodies derived from patients with connective tissue disease Lupus 2006, 15:865-72 10.1177/0961203306071405 17211992
37. Nemerow GR Cooper NR Isolation of Epstein Barr-virus and studies of its neutralization by human IgG and complement J Immunol 1981, 127:272-278 6263973
38. Huber M von Wyl V Ammann CG Kuster H Stiegler G Katinger H Weber R Fischer M Stoiber H Günthard HF Trkola A Potent HIV-Neutralizing and Complement Lysis Activity of Antibodies Are Not Obligatorily Linked J Virol 2008, 82:3834-42 2293011 18234794 10.1128/JVI.02569-07
39. Schmitz JE Johnson RP McClure HM Manson KH Wyand MS Kuroda MJ Lifton MA Khunkhun RS McEvers KJ Gillis J Piatak M Lifson JD Grosschupff G Racz P Tenner-Racz K Rieber EP Kuus-Reichel K Gelman RS Letvin NL Montefiori DC Ruprecht RM Desrosiers RC Reimann KA Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques J Virol 2005, 79:8131-41 1143721 15956558 10.1128/ JVI.79.13.8131-8141.2005
40. Stahl-Hennig C Dittmer U Nisslein T Petry H Jurkiewicz E Fuchs D Wachter H Mätz-Rensing K Kuhn EM Kaup FJ Rud EW Hunsmann G Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus J Gen Virol 1996, 77:2969-81 10.1099/ 0022-1317-77-12-2969 9000087
41. Stahl-Hennig C Eisenblatter M Franz M Stoiber H Tenner-Racz K Suh YS Jasny E Falkensammer B Ugucchioni M Georgsson G Baroni C Dierich MP Lifson JD Steinman RM Uberla K Racz P Ignatius R A single vaccination with attenuated SIVmac 239 via the tonsillar route confers partial protection against challenge with SIVmac 251 at a distant mucosal site, the rectum Front Biosci 2007, 12:2107-23 10.2741/2215 17127448
42. Kuate S Stahl-Hennig C Stoiber H Nchinda G Floto A Franz M Sauermann U Bredl S Deml L Ignatius R Norley S Racz P Tenner-Racz K Steinman RM Wagner R Uberla K Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus Virology 2006, 351:133-44 10.1016/j.virol.2006.03.009 16616946
43. Stahl-Hennig C Steinman RM Tenner-Racz K Pope M Stolte N Mätz-Rensing K Grobschupff G Raschdorff B Hunsmann G Racz P Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus Science 1999, 285:1261-5 10.1126/ science.285.5431.1261 10455052
44. Schnell T Foley P Wirth M Münch J Überla K Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus Hum Gene Ther 2000, 11:439-447 10.1089/ 10430340050015905 10697118
45. He TC Zhou S da Costa LT Yu J Kinzler KW Vogelstein B A simplified system for generating recombinant adenoviruses Proc Natl Acad Sci USA 1998, 95:2509-14 19394 9482916 10.1073/pnas.95.5.2509
46. Letvin NL Progress in the development of an HIV-1 vaccine Science 1998, 280:1875-80 10.1126/science.280.5371.1875 9632379
47. Spring M Stahl-Hennig C Nisslein T Locher C Fuchs D Bodemer W Hunsmann G Dittmer U Suppression of viral replication in a long-term non-progressing rhesus macaque experimentally infected with pathogenic simian immunodeficiency virus (SIV) Clin Immunol Immunopathol 1998, 87:101-105 10.1006/clin.1997.4511 9576016
48. Hofmann-Lehmann R.Swenerton RK Liska V Leutenegger CM Lutz H McClure HM Ruprecht RM Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems AIDS Res Hum Retroviruses 2000, 16:1247-57 10.1089/08892220050117014 10957722
49. Akari H Mori K Terao K Otani I Fukasawa M Mukai R Yoshikawa Y In vitro immortalization of Old World monkey T lymphocytes with Herpesvirus saimiri: Its susceptibility to infection with simian immunodeficiency viruses Virology 1996, 218:382-8 10.1006/viro.1996.0207 8610465
50. Frank I Stoiber H Godar S Stockinger H Steindl F Katinger HW Dierich MP Acquisition of host cell-surface-derived molecules by HIV-1 AIDS 1996, 10:1611-20 8970680